These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19377284)

  • 1. A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus.
    Guttormsen HK; Mascuch SJ; West JC; Paoletti LC
    Hum Vaccin; 2009 Jul; 5(7):461-6. PubMed ID: 19377284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.
    Fabbrini M; Sammicheli C; Margarit I; Maione D; Grandi G; Giuliani MM; Mori E; Nuti S
    J Immunol Methods; 2012 Apr; 378(1-2):11-9. PubMed ID: 22309986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells.
    Guttormsen HK; Liu Y; Paoletti LC
    Hum Vaccin; 2008; 4(5):370-4. PubMed ID: 18398304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.
    Choi MJ; Noh JY; Cheong HJ; Kim WJ; Lin SM; Zhi Y; Lim JH; Lim S; Seo HS; Song JY
    Hum Vaccin Immunother; 2018 Jan; 14(1):67-73. PubMed ID: 28933634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an opsonophagocytic killing assay for group a streptococcus.
    Jones S; Moreland NJ; Zancolli M; Raynes J; Loh JMS; Smeesters PR; Sriskandan S; Carapetis JR; Fraser JD; Goldblatt D
    Vaccine; 2018 Jun; 36(26):3756-3763. PubMed ID: 29776751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against
    Salehi S; Hohn CM; Penfound TA; Dale JB
    mSphere; 2018 Dec; 3(6):. PubMed ID: 30567901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Multiplex Immunoassays for Quantification of IgG against Group B
    Buffi G; Galletti B; Stella M; Proietti D; Balducci E; Romano MR; Mori E; Fabbrini M; Giuliani MM; Berti F; Margarit I
    mSphere; 2019 Aug; 4(4):. PubMed ID: 31391276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of complement and antibody in opsonophagocytosis of type II group B streptococci.
    Baker CJ; Webb BJ; Kasper DL; Edwards MS
    J Infect Dis; 1986 Jul; 154(1):47-54. PubMed ID: 3519791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of complement and complement receptor C1qR in the antibody-independent killing of group B streptococcus.
    Butko P; Nicholson-Weller A; Wessels MR
    Adv Exp Med Biol; 1997; 418():941-3. PubMed ID: 9331805
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
    Butko P; Nicholson-Weller A; Wessels MR
    J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum.
    Fischer GW; Hunter KW; Wilson SR
    Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type III group B Streptococcus: functional interaction with IgG subclass antibodies.
    Givner LB; Baker CJ; Edwards MS
    J Infect Dis; 1987 Mar; 155(3):532-9. PubMed ID: 3543156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-independent and -dependent opsonization of group B Streptococcus requires the first component of complement C1.
    Levy NJ; Kasper DL
    Infect Immun; 1985 Jul; 49(1):19-24. PubMed ID: 3891622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of complement receptors in opsonophagocytosis of group B streptococci by adult and neonatal neutrophils.
    Smith CL; Baker CJ; Anderson DC; Edwards MS
    J Infect Dis; 1990 Aug; 162(2):489-95. PubMed ID: 2197341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination With a Latch Peptide Provides Serotype-Independent Protection Against Group B Streptococcus Infection in Mice.
    Lin SM; Jang AY; Zhi Y; Gao S; Lim S; Lim JH; Song JY; Sullam PM; Rhee JH; Seo HS
    J Infect Dis; 2017 Dec; 217(1):93-102. PubMed ID: 29106586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapulmonary bacterial clearance of type III group B streptococcus is reduced in preterm compared with term rabbits and occurs independent of antibody.
    Hall SL; Sherman MP
    Am Rev Respir Dis; 1992 May; 145(5):1172-7. PubMed ID: 1586063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the opsonic requirements of group B streptococcus type III.
    Hastings MJ; Easmon CS
    Br J Exp Pathol; 1981 Oct; 62(5):519-25. PubMed ID: 7028075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of complement in opsonization of GBS.
    Edwards MS; Kasper DL; Nicholson-Weller A; Baker CJ
    Antibiot Chemother (1971); 1985; 35():170-89. PubMed ID: 3901894
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci.
    Albanyan EA; Edwards MS
    Infect Immun; 2000 Oct; 68(10):5794-802. PubMed ID: 10992487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.